Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... and experimental drugs for COVID-19.

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance ... Pfizer—which has taken flak for failing to make good on its immense COVID-19 profits—is expected to slip in the rankings of ...

While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations.

A group of lawmakers are urging President Donald Trump to reject pharmaceutical companies’ efforts to pause the Biden ...

A letter from several Democratic Senators urged Trump to use his deal-making skills to “flat out reject any request to end ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.